Ever need a fact or quotation on "gangliosides"? Designed for speechwriters, journalists, writers, researchers, students, professors, teachers, historians, academics, scrapbookers, trivia buffs and word lovers, this is the largest book ever created for this word. It represents a compilation of "single sentences" and/or "short paragraphs" from a variety of sources with a linguistic emphasis on anything relating to the term "gangliosides," including non-conventional usage and alternative meanings which capture ambiguities. This is not an encyclopedic book, but rather a collage of statements made using the word "gangliosides," or related words (e.g. inflections, synonyms or antonyms). This title is one of a series of books that considers all major vocabulary words. The entries in each book cover all parts of speech (noun, verb, adverb or adjective usage) as well as use in modern slang, pop culture, social sciences (linguistics, history, geography, economics, sociology, political science), business, computer science, literature, law, medicine, psychology, mathematics, chemistry, physics, biology and other physical sciences. This data dump results in many unexpected examples for "gangliosides," since the editorial decision to include or exclude terms is purely a computer-generated linguistic process. The resulting entries are used under license or with permission, used under fair use conditions, used in agreement with the original authors, or are in the public domain.
Book Description
Editorial Reviews
Excerpt. © Reprinted by permission. All rights reserved.
Nonfiction Usage
Journalism Usage
Ronald Schnaar - News: April 27, 2002 — Headline: Scientists Developing Ways to Enhance Nerve Regeneration. Excerpt: "But the field has come a long way in the last decade and there is now hope that through understanding all the different ways in which axons are inhibited from regenerating, we can combine technologies and find ways to enhance nerve regeneration in the future. We have demonstrated that particular molecules on the nerve cell surface, called gangliosides, are involved in signals that the nerve cells receive that limit their ability to regenerate," he said.
Patent Usage
Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies: Patented by Ana Maria Vazguez Lopez, Rolando Perez Rodriguez, Eladio Iglesis Guerra, Alexis Perez, Gumersinda Bombino Lopez and Irene Beausolei Delgado on January 9, 1998. Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-idiotype monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.
Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics: Patented by Michel Gilbert and Warren W. Wakarchuk on January 1, 2000. Abstract: This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an .alpha.2,3- and an .alpha.2,8-activity. A .beta.1,4-GalNAc transferase and a .beta.1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.
C-glycoside analogs and methods for their preparation and use: Patented by Robert J. Linhardt, Helene G. Bazin, Yuguo Du and Tulay Polat on August 9, 1999. Abstract: The invention provides versatile sialic acid C-glycoside precursors that are useful for preparing C-glycoside analogs of Gangliosides, peptides, and proteins, as well as synthetic intermediates useful for the preparation of the precursors, and synthetic methods useful for preparing the precursors and the intermediates. The invention also provides gangliosides, peptides, and proteins that comprise sialic acid C-glycoside components, as well as synthetic methods useful for the preparation of such compounds.
Chemo-enzymatic Synthesis of Sialylated Oligosaccharides: Patented by Shawn Defrees and Edward J. Mcguire on August 1, 2002. Abstract: In vitro/cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel compounds that comprise sphingoid groups are disclosed. The compounds include sialylated oligosaccharides including gangliosides as well as various sphingoids and ceramides.
Compositions Containing Gangliosides for Use in the Treatment of Skin Disorders: Patented by Amy S. Paller on December 7, 2001. Abstract: The invention is a pharmacological composition that contains at least one ganglioside or portion thereof. The composition can be used to treat skin disorders.
Detection of Antibodies to Gangliosides: Patented by Normand J. Robichaud and Louis P. Kertiles on May 3, 2001. Abstract: Method of detecting antibodies to one or more ganglioside(s) of interest in a sample are disclosed which comprise using a solid-phase reactant having carbonyl groups attached thereon, and the ganglioside(s) of interest linked to the solid-phase reactant by an amide bond between an amino group of ganglioside of interest and a carbonyl group attached to the solid-phase reactant. The methods of detecting antibodies to ganglioside(s) of interest can be used in methods of diagnosing neuropathies in an individual.
Enzymatic synthesis of gangliosides: Patented by Shawn DeFrees on August 2, 2001. Abstract: This invention provides methods for practical in vitro synthesis of gangliosides and other glycolipids. The synthetic methods typically involve enzymatic synthesis, or a combination of enzymatic and chemical synthesis. One or more of the enzymatic steps is preferably carried out in the presence of an organic solvent.
Ganglioside Immunostimulating Complexes and Uses Thereof: Patented by John C. Cox, Bengt J. Ronnberg Lennart and Sigrid E. Sjolander on June 12, 1998. Abstract: The present invention relates generally to an immunostimulating complex comprising one or more gangliosides and more particularly to an immunostimulating complex comprising at least one of the gangliosides GM2, GD2, GD3 or GT3. The present invention is useful, inter alia , as a prophylactic and/or therapeutic agent in the treatment of tumours, and more particularly, melanomas.
Gangliosides with immunosuppressive ceramide moieties: Patented by Stephan Ladisch on February 3, 1993. Abstract: A method for suppressing immune responses in animals by administering a mixture of gangliosides to the animal where the gangliosides have heterogeneous ceramide structures containing fatty acid portions with carbon chain lengths of 21-30 or less than 18 carbon atoms. Ganglioside mixtures which are homogeneous with respect to the fatty acid portion are also effective immunosuppressive agents when the carbon chain length of the fatty acid portion is less than 18. Compositions containing the above specified ganglioside mixtures are also disclosed.
... --This text refers to the Digital edition.
Journalism Usage
Ronald Schnaar - News: April 27, 2002 — Headline: Scientists Developing Ways to Enhance Nerve Regeneration. Excerpt: "But the field has come a long way in the last decade and there is now hope that through understanding all the different ways in which axons are inhibited from regenerating, we can combine technologies and find ways to enhance nerve regeneration in the future. We have demonstrated that particular molecules on the nerve cell surface, called gangliosides, are involved in signals that the nerve cells receive that limit their ability to regenerate," he said.
Patent Usage
Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies: Patented by Ana Maria Vazguez Lopez, Rolando Perez Rodriguez, Eladio Iglesis Guerra, Alexis Perez, Gumersinda Bombino Lopez and Irene Beausolei Delgado on January 9, 1998. Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-idiotype monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.
Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics: Patented by Michel Gilbert and Warren W. Wakarchuk on January 1, 2000. Abstract: This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an .alpha.2,3- and an .alpha.2,8-activity. A .beta.1,4-GalNAc transferase and a .beta.1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.
C-glycoside analogs and methods for their preparation and use: Patented by Robert J. Linhardt, Helene G. Bazin, Yuguo Du and Tulay Polat on August 9, 1999. Abstract: The invention provides versatile sialic acid C-glycoside precursors that are useful for preparing C-glycoside analogs of Gangliosides, peptides, and proteins, as well as synthetic intermediates useful for the preparation of the precursors, and synthetic methods useful for preparing the precursors and the intermediates. The invention also provides gangliosides, peptides, and proteins that comprise sialic acid C-glycoside components, as well as synthetic methods useful for the preparation of such compounds.
Chemo-enzymatic Synthesis of Sialylated Oligosaccharides: Patented by Shawn Defrees and Edward J. Mcguire on August 1, 2002. Abstract: In vitro/cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel compounds that comprise sphingoid groups are disclosed. The compounds include sialylated oligosaccharides including gangliosides as well as various sphingoids and ceramides.
Compositions Containing Gangliosides for Use in the Treatment of Skin Disorders: Patented by Amy S. Paller on December 7, 2001. Abstract: The invention is a pharmacological composition that contains at least one ganglioside or portion thereof. The composition can be used to treat skin disorders.
Detection of Antibodies to Gangliosides: Patented by Normand J. Robichaud and Louis P. Kertiles on May 3, 2001. Abstract: Method of detecting antibodies to one or more ganglioside(s) of interest in a sample are disclosed which comprise using a solid-phase reactant having carbonyl groups attached thereon, and the ganglioside(s) of interest linked to the solid-phase reactant by an amide bond between an amino group of ganglioside of interest and a carbonyl group attached to the solid-phase reactant. The methods of detecting antibodies to ganglioside(s) of interest can be used in methods of diagnosing neuropathies in an individual.
Enzymatic synthesis of gangliosides: Patented by Shawn DeFrees on August 2, 2001. Abstract: This invention provides methods for practical in vitro synthesis of gangliosides and other glycolipids. The synthetic methods typically involve enzymatic synthesis, or a combination of enzymatic and chemical synthesis. One or more of the enzymatic steps is preferably carried out in the presence of an organic solvent.
Ganglioside Immunostimulating Complexes and Uses Thereof: Patented by John C. Cox, Bengt J. Ronnberg Lennart and Sigrid E. Sjolander on June 12, 1998. Abstract: The present invention relates generally to an immunostimulating complex comprising one or more gangliosides and more particularly to an immunostimulating complex comprising at least one of the gangliosides GM2, GD2, GD3 or GT3. The present invention is useful, inter alia , as a prophylactic and/or therapeutic agent in the treatment of tumours, and more particularly, melanomas.
Gangliosides with immunosuppressive ceramide moieties: Patented by Stephan Ladisch on February 3, 1993. Abstract: A method for suppressing immune responses in animals by administering a mixture of gangliosides to the animal where the gangliosides have heterogeneous ceramide structures containing fatty acid portions with carbon chain lengths of 21-30 or less than 18 carbon atoms. Ganglioside mixtures which are homogeneous with respect to the fatty acid portion are also effective immunosuppressive agents when the carbon chain length of the fatty acid portion is less than 18. Compositions containing the above specified ganglioside mixtures are also disclosed.
... --This text refers to the Digital edition.
Product Details
Would you like to update product info or give feedback on images?
|
Customer Reviews
|
There are no customer reviews yet.
|
|||
|
Video reviews
|
Inside This Book
(learn more)
Browse Sample Pages:
Front Cover | Table of Contents | First Pages | Index | Back Cover | Surprise Me!
Front Cover | Table of Contents | First Pages | Index | Back Cover | Surprise Me!
Tag this product(What's this?)Think of a tag as a keyword or label you consider is strongly related to this product.
Tags will help all customers organize and find favorite items. |
Sell a Digital Version of This Book in the Kindle Store
If you are a publisher or author and hold the digital rights to a book, you can sell a digital version of it in our Kindle Store.
Learn more
